Interventional Radiology, University Hospitals Leuven, Leuven, Belgium.
Department of Paediatric and Congenital Cardiology, University Hospitals Leuven, Leuven, Belgium.
Catheter Cardiovasc Interv. 2019 Dec 1;94(7):996-1002. doi: 10.1002/ccd.28501. Epub 2019 Oct 9.
To determine the feasibility and clinical result of selective embolization of hepatoduodenal or paratracheal lymphatics in Fontan patients with protein-losing enteropathy (PLE) or plastic bronchitis (PB).
Dilated lymph vessels in periportal (PLE) or paratracheal (PB) position were percutaneously punctured with a 22G Chiba needle. Intralymphatic position was confirmed by water soluble contrast injection with drainage to hepatoduodenal or tracheal fistulae. After flushing with 10% glucose solution, occlusion of hepatoduodenal or paratreacheal lymphatics was effected by injection of 1-4 cc mixture 4/1 of Lipiodol/n-butyl cyanoacrylate (n-BCA; Histoacryl).
Seven patients with proven PLE were treated with periportal lymphatic embolization 10.7 (range: 6.6-13.5) years after the Fontan operation. The Fontan operation was performed at a median age of 3.7 (range: 2.9-5.7) years and PLE started a median of 3.1 (range: 0.9-4.7) years later. Five patients required a second procedure 2-8 months later. Complications were limited (spillage of glue in portal branch, transient cholangitis, and caustic duodenal bleeding). Six of seven patients reported significant improvement in quality of life and normalization of albumin levels after limited follow-up (p < .01). One patient (Fontan at 2.9 years; age 16.4 years) had PB for 2 years. Selective transthoracic cone-beam-directed puncture of left and right paratracheal lymphatics with n-BCA embolization of distal lymphatic fistulae resulted in lasting absence of tracheal casts (11 months).
Embolization of periportal/peritracheal lymphatics is a promising technique in Fontan patients with PLE/PB. Larger series are required to determine incidence and reasons of success/failure, with long-term results and effects on liver function.
为了确定选择性栓塞肝十二指肠或气管旁淋巴管在有蛋白丢失性肠病(PLE)或塑型性支气管炎(PB)的 Fontan 患者中的可行性和临床结果。
用 22G Chiba 针经皮穿刺门脉周围(PLE)或气管旁(PB)扩张的淋巴管。通过向肝十二指肠或气管瘘注水确认淋巴管内位置。用 10%葡萄糖溶液冲洗后,用 1-4cc 混合 4/1 的碘油/正丁基氰基丙烯酸酯(n-BCA;Histoacryl)注射闭塞肝十二指肠或气管旁淋巴管。
7 例经证实的 PLE 患者在 Fontan 手术后 10.7 年(范围:6.6-13.5 年)接受了门脉周围淋巴管栓塞治疗。Fontan 手术中位年龄为 3.7 岁(范围:2.9-5.7 岁),PLE 中位开始年龄为 3.1 岁(范围:0.9-4.7 岁)。5 例患者在 2-8 个月后需要进行第二次手术。并发症有限(胶溢出到门静脉分支、短暂性胆管炎和腐蚀性十二指肠出血)。在有限的随访中,7 例患者中有 6 例报告生活质量显著改善,白蛋白水平正常化(p < .01)。1 例(Fontan 手术 2.9 岁;年龄 16.4 岁)有 2 年的 PB。通过选择性经胸锥形束定向穿刺左、右气管旁淋巴管,并对远端淋巴管瘘进行 n-BCA 栓塞,导致气管铸型持续缺失(11 个月)。
在有 PLE/PB 的 Fontan 患者中,栓塞门脉周围/气管旁淋巴管是一种有前途的技术。需要更大的系列来确定成功率/失败率的发生率和原因,以及长期结果和对肝功能的影响。